FDA's Delay of Lilly's Alzheimer's Drug Donanemab Sends Stock Tumbling
TL;DR Summary
Eli Lilly stock dropped 3.2% after the FDA delayed its decision on the Alzheimer's drug candidate, donanemab, due to concerns about its safety and efficacy. The company remains confident in the drug's potential and is committed to working with the FDA to address any questions or concerns.
- Why Eli Lilly Stock Flopped on Friday Yahoo Finance
- F.D.A. Delays Action on Closely Watched Alzheimer's Drug The New York Times
- Eli Lilly hits another Alzheimer's hurdle. But obesity, diabetes GLP-1s strong CNBC
- In an unusual move, FDA postpones approval decision for Lilly’s Alzheimer’s drug NBC News
- Lilly's donanemab delayed as FDA seeks late advisory meeting Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
2 min
vs 3 min read
Condensed
89%
424 → 47 words
Want the full story? Read the original article
Read on Yahoo Finance